ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications

ZURICH, Switzerland, Sept. 8 ESBATech AG, a leadingdeveloper of antibody fragment therapeutics, today announced that the companyhas successfully completed its Phase I clinical study of the company's leadproduct candidate, ESBA105, in ophthalmic indications. In April 2008, ESBATechinitiated the Phase I study designed to evaluate the safety, tolerability andpharmacokinetic profile of ESBA105, when delivered topically via eye drops inhealthy volunteers. This trial was conducted as a single and repeated doseescalation study in Switzerland. ESBA105 is a single-chain antibody fragmentdirected against TNF-alpha, and it is being developed initially for ophthalmicindications. Several additional clinical studies are in the preparationstages.

Manfred Zierhut, Professor in the Department of Ophthalmology at theUniversity of Tuebingen in Germany, will present preclinical pharmacokineticdata on ESBA105 on Friday, September 12, 2008, at the 7th InternationalSymposium on Uveitis in Constance, Germany. For more information on thesymposium and on Prof. Zierhut's abstract, please visit www.iusg2008.org/.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented,"The completion of this Phase I study with ESBA105 in ophthalmic indicationsmarks a critical clinical milestone for the company. Recently, ESBATechsecured CHF 23M (USD 22M) in an extended Series B venture financing round.This financing will fund further clinical studies with ESBA105 in ophthalmicindications, as well as build broad franchises in ophthalmology, rheumatologyand respiratory diseases for ESBA105 and other antibody fragments. We lookforward to announcing the results of this Phase I study and future clinicaltrials."

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG,commented, "We are encouraged by the safety and pharmacokinetic profile thatESBA105 has demonstrated in this Phase I study and we look forward tocontinuing our progress in the clinical development of this product."

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discoveryand development company focused on advancing antibody fragments fortherapeutic applications. The company applies its proprietary, fully humansingle-chain antibody frameworks to generate product candidates againsttargets of clinical relevance. ESBATech is focused on delivering highconcentrations of its therapeutic antibody fragments to the targeted sites, incombination with extremely low systemic load, in order to achieve low risk ofsystemic drug reactions using topical and local delivery.

Current venture investors include SV Life Sciences, Clarus Ventures, HBMBioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest and VIPartners. For more information about ESBATech, please visit, www.esbatech.com.

SOURCE ESBATech AG

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...